The growth of the generic drug market is four times higher than the pharmaceutical market overall, and generics are poised to take an even bigger bite of the prescription drug market as more branded drugs go off patent.
While it is possible to project generic launches based on U.S. Food and Drug Administration (FDA) approvals (published in the "Orange Book") and the date a branded drug is to expire, there are many factors that put generic launches at risk, according to Diana Papshev, Pharm D, a partner with DrugManagementForum.com. Papshev outlined the projected generic launches at the April 2011 meeting of the Academy of Managed Care Pharmacy.
Generic launches projected for 2011:
Zyprexa Zyris, antipsychotic
Generic launches anticipated for 2012:
Actoplus Met, diabetes
Diovan HCT, diabetes
Focatin XR, stimulant
Lescol XL, cardiovascular